Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Peter H Wiernik; Izidore S Lossos; Joseph M Tuscano; Glen Justice; Julie M Vose; Craig E Cole; Wendy Lam; Kyle McBride; Kenton Wride; Dennis Pietronigro; Kenichi Takeshita; Annette Ervin-Haynes; Jerome B Zeldis; Thomas M Habermann

doi:10.1200/JCO.2007.15.3429

Back

$Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma$

Journal article

Peer reviewed

Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Peter H Wiernik, Izidore S Lossos, Joseph M Tuscano, Glen Justice, Julie M Vose, Craig E Cole, Wendy Lam, Kyle McBride, Kenton Wride, Dennis Pietronigro, …

Journal of clinical oncology, Vol.26(30), pp.4952-4957

2008-10-20

DOI: https://doi.org/10.1200/JCO.2007.15.3429

PMID: 18606983

Abstract

PurposeThe major cause of death in aggressive lymphoma is relapse or nonresponse to initial therapy. Lenalidomide has activity in a variety of hematologic malignancies, including non-Hodgkin's lymphoma (NHL). We report the results of a phase II, single-arm, multicenter trial evaluating the safety and efficacy of lenalidomide oral monotherapy in patients with relapsed or refractory aggressive NHL.Patients and MethodsPatients were treated with oral lenalidomide 25 mg once daily on days 1 to 21, every 28 days, for 52 weeks, until disease progression or intolerance. The primary end point was response; secondary end points included duration of response, progression-free survival (PFS), and safety.ResultsForty-nine patients with a median age of 65 years received lenalidomide in this study. The most common histology was diffuse large B-cell lymphoma (53%), and patients had received a median of four prior treatment regimens for NHL. An objective response rate of 35% was observed in 49 treated patients, including a 12% rate of complete response/unconfirmed complete response. Responses were observed in each aggressive histologic subtype tested (diffuse large B-cell, follicular center grade 3, mantle cell, and transformed lymphomas). Of patients with stable disease or partial response at first assessment, 25% improved with continued treatment. Estimated median duration of response was 6.2 months, and median PFS was 4.0 months. The most common grade 4 adverse events were neutropenia (8.2%) and thrombocytopenia (8.2%); the most common grade 3 adverse events were neutropenia (24.5%), leukopenia (14.3%), and thrombocytopenia (12.2%).ConclusionOral lenalidomide monotherapy is active in relapsed or refractory aggressive NHL, with manageable side effects.

Metrics

163 Record Views

321 Times Cited - Web of Science

See more details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Industry collaboration; Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.130 Lymphomas; 1.130.132 Lymphoma
Web Of Science research areas: Oncology
ESI research areas: Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Creators: Peter H Wiernik - From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; University of California, Davis Cancer Center, Sacramento; Pacific Coast Hematology/Oncology Medical Group, Fountain Valley, CA; University of Nebraska, Nebraska Medical Center, Omaha, NE; Gundersen Clinic, La Crosse, WI; BC Community Oncology Trialists, Burnaby, British Columbia, Canada; Instat Services, Chatham; Celgene Corporation, Summit, NJ; and Mayo
Izidore S Lossos - From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; University of California, Davis Cancer Center, Sacramento; Pacific Coast Hematology/Oncology Medical Group, Fountain Valley, CA; University of Nebraska, Nebraska Medical Center, Omaha, NE; Gundersen Clinic, La Crosse, WI; BC Community Oncology Trialists, Burnaby, British Columbia, Canada; Instat Services, Chatham; Celgene Corporation, Summit, NJ; and Mayo
Joseph M Tuscano - From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; University of California, Davis Cancer Center, Sacramento; Pacific Coast Hematology/Oncology Medical Group, Fountain Valley, CA; University of Nebraska, Nebraska Medical Center, Omaha, NE; Gundersen Clinic, La Crosse, WI; BC Community Oncology Trialists, Burnaby, British Columbia, Canada; Instat Services, Chatham; Celgene Corporation, Summit, NJ; and Mayo
Glen Justice - From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; University of California, Davis Cancer Center, Sacramento; Pacific Coast Hematology/Oncology Medical Group, Fountain Valley, CA; University of Nebraska, Nebraska Medical Center, Omaha, NE; Gundersen Clinic, La Crosse, WI; BC Community Oncology Trialists, Burnaby, British Columbia, Canada; Instat Services, Chatham; Celgene Corporation, Summit, NJ; and Mayo
Julie M Vose - From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; University of California, Davis Cancer Center, Sacramento; Pacific Coast Hematology/Oncology Medical Group, Fountain Valley, CA; University of Nebraska, Nebraska Medical Center, Omaha, NE; Gundersen Clinic, La Crosse, WI; BC Community Oncology Trialists, Burnaby, British Columbia, Canada; Instat Services, Chatham; Celgene Corporation, Summit, NJ; and Mayo
Craig E Cole - From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; University of California, Davis Cancer Center, Sacramento; Pacific Coast Hematology/Oncology Medical Group, Fountain Valley, CA; University of Nebraska, Nebraska Medical Center, Omaha, NE; Gundersen Clinic, La Crosse, WI; BC Community Oncology Trialists, Burnaby, British Columbia, Canada; Instat Services, Chatham; Celgene Corporation, Summit, NJ; and Mayo
Wendy Lam - From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; University of California, Davis Cancer Center, Sacramento; Pacific Coast Hematology/Oncology Medical Group, Fountain Valley, CA; University of Nebraska, Nebraska Medical Center, Omaha, NE; Gundersen Clinic, La Crosse, WI; BC Community Oncology Trialists, Burnaby, British Columbia, Canada; Instat Services, Chatham; Celgene Corporation, Summit, NJ; and Mayo
Kyle McBride - From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; University of California, Davis Cancer Center, Sacramento; Pacific Coast Hematology/Oncology Medical Group, Fountain Valley, CA; University of Nebraska, Nebraska Medical Center, Omaha, NE; Gundersen Clinic, La Crosse, WI; BC Community Oncology Trialists, Burnaby, British Columbia, Canada; Instat Services, Chatham; Celgene Corporation, Summit, NJ; and Mayo
Kenton Wride - From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; University of California, Davis Cancer Center, Sacramento; Pacific Coast Hematology/Oncology Medical Group, Fountain Valley, CA; University of Nebraska, Nebraska Medical Center, Omaha, NE; Gundersen Clinic, La Crosse, WI; BC Community Oncology Trialists, Burnaby, British Columbia, Canada; Instat Services, Chatham; Celgene Corporation, Summit, NJ; and Mayo
Dennis Pietronigro - From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; University of California, Davis Cancer Center, Sacramento; Pacific Coast Hematology/Oncology Medical Group, Fountain Valley, CA; University of Nebraska, Nebraska Medical Center, Omaha, NE; Gundersen Clinic, La Crosse, WI; BC Community Oncology Trialists, Burnaby, British Columbia, Canada; Instat Services, Chatham; Celgene Corporation, Summit, NJ; and Mayo
Kenichi Takeshita - From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; University of California, Davis Cancer Center, Sacramento; Pacific Coast Hematology/Oncology Medical Group, Fountain Valley, CA; University of Nebraska, Nebraska Medical Center, Omaha, NE; Gundersen Clinic, La Crosse, WI; BC Community Oncology Trialists, Burnaby, British Columbia, Canada; Instat Services, Chatham; Celgene Corporation, Summit, NJ; and Mayo
Annette Ervin-Haynes - From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; University of California, Davis Cancer Center, Sacramento; Pacific Coast Hematology/Oncology Medical Group, Fountain Valley, CA; University of Nebraska, Nebraska Medical Center, Omaha, NE; Gundersen Clinic, La Crosse, WI; BC Community Oncology Trialists, Burnaby, British Columbia, Canada; Instat Services, Chatham; Celgene Corporation, Summit, NJ; and Mayo
Jerome B Zeldis - From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; University of California, Davis Cancer Center, Sacramento; Pacific Coast Hematology/Oncology Medical Group, Fountain Valley, CA; University of Nebraska, Nebraska Medical Center, Omaha, NE; Gundersen Clinic, La Crosse, WI; BC Community Oncology Trialists, Burnaby, British Columbia, Canada; Instat Services, Chatham; Celgene Corporation, Summit, NJ; and Mayo
Thomas M Habermann - From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; University of California, Davis Cancer Center, Sacramento; Pacific Coast Hematology/Oncology Medical Group, Fountain Valley, CA; University of Nebraska, Nebraska Medical Center, Omaha, NE; Gundersen Clinic, La Crosse, WI; BC Community Oncology Trialists, Burnaby, British Columbia, Canada; Instat Services, Chatham; Celgene Corporation, Summit, NJ; and Mayo
Publication Details: Journal of clinical oncology, Vol.26(30), pp.4952-4957
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
PMID: 18606983
Record Identifier: 991031559386902976